Sun Pharma and Moebius Medical announced that their intra-articular injection MM-II showed greater pain relief than placebo for up to 26 weeks in osteoarthritis (OA) patients, based on clinical trial data. The study demonstrated that from weeks 12 to 26, more patients on MM-II experienced significant pain improvement compared to those on placebo. MM-II, a novel non-opioid, uses a proprietary suspension of liposomes to reduce joint friction and pain. The companies plan to initiate a Phase 3 clinical program and seek a CE Mark for the product in the European Union.